Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ovapuldencel-T - AiVita Biomedical

Next Previous
Drug Profile

Ovapuldencel-T - AiVita Biomedical

Alternative Names: AV-OVA-1; Ovarian cancer stem cell therapy - AiVita Biomedical; Ovarian cancer stem cell therapy - NeoStem Oncology

Latest Information Update: 05 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hoag Memorial Hospital Presbyterian
  • Developer AiVita Biomedical; NeoStem Oncology
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 02 Jun 2023 Interim adverse events and efficacy data from a phase-II trial in Ovarian, Peritoneal and Fallopian tube cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023) (NCT02033616)
  • 28 May 2021 Aivita completes enrollment in phase-II clinical trials in Ovarian, Peritoneal and Fallopian tube cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT02033616)
  • 24 Sep 2020 Phase II development is ongoing for Fallopian tube cancer in USA (AIVITA Biomedical pipeline, September 2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top